Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Medacta Group SA    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Medacta : Announces First U.S. Surgery with MectaScrew PEEK following FDA Clearance

share with twitter share with LinkedIn share with facebook
share via e-mail
11/04/2019 | 01:05pm EST


EQS Group-Media / 04.11.2019 / 19:00

Media Release
Medacta Announces First U.S. Surgery with MectaScrew PEEK following FDA Clearance

CASTEL SAN PIETRO, 4 November 2019 - Medacta is proud to announce the successful completion of the first U.S. surgery utilizing its MectaScrew PEEK Interference Screw for ligament refixation.

The MectaScrew PEEK, which received clearance from the U.S. Food and Drug Administration (FDA) in June, is one of Medacta's most recent sports medicine offerings. As part of the Medacta Single Bundle ACL set, it is intended for knee arthroscopy and indicated for reconstructive treatment of ruptured anterior and posterior cruciate ligaments for hamstring and bone-tendon-bone repairs.

The MectaScrew PEEK features several noteworthy design features, including a blunt thread, which protects the graft from laceration, while ensuring fixation strength, as well as sharp threads at the driver tip that gradually increase in width as the screw goes from distal to proximal to facilitate screw insertion. The associated driver also features a tip design that enables strong retention of the screw once positioned on the tip of the instrument.

The first single bundle ACL surgery in the United States was completed by Akbar Nawab, M.D., at Ellis and Badenhausen Orthopaedics (Louisville, Kentucky) on September 24. "The implant and associated instrumentation performed very well," said Dr. Nawab. "The screw started nicely and provided secure fixation without any damage to the graft, while the instrumentation's ergonomic design made each instrument easy and natural to use. I feel very confident starting my patient in an accelerated rehabilitation program."

This surgery follows the first single bundle ACL performed in Australia in August 2019 and is the start of Medacta's sports medicine presence in the United States.

Contact
Medacta International SA
Gianluca Olgiati
Senior Director Global Marketing
Phone: +41 91 696 60 60
media@medacta.ch

About Medacta
Medacta is an international company specializing in the design and production of innovative orthopaedic products and the development of accompanying surgical techniques for joint replacement, spine surgery, and sports medicine. Established in 1999 in Switzerland, Medacta's products and surgical techniques are characterized by innovation. Medacta is a pioneer in developing new offerings on the basis of minimally invasive surgical techniques, in particular its Anterior Minimally Invasive Surgery ("AMIS") technique for hip replacements. Medacta has leveraged its orthopaedic expertise and comprehensive understanding of the human body to develop the sophisticated "MySolutions" technology, which offers surgeons highly personalized pre-operative planning and implant placement methodologies by creating advanced personalized kinematic models and 3D planning tools for use in hip, knee, shoulder and spine procedures.



Issuer: Medacta Group SA
Key word(s): Advertisement/Communication

End of Corporate News


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch, investor.relations@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 903815

 
End of News EQS Group Media

903815  04.11.2019 

fncls.ssp?fn=show_t_gif&application_id=903815&application_name=news&site_id=zonebourse

© EQS 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MEDACTA GROUP SA
02/19MEDACTA GROUP SA : Interim award in microport case
EQ
01/23MEDACTA : Announces Several First-time Surgeries and CE Marking for Multiple Pro..
EQ
01/21MEDACTA : revenue up by 14%, with a strong revenue growth above the market in al..
EQ
2019MEDACTA : Receives FDA Clearance for MyShoulder Placement Guides
EQ
2019MEDACTA : announces a revision of the full year guidance
EQ
2019MEDACTA : Announces First U.S. Surgery with MectaScrew PEEK following FDA Cleara..
EQ
2019MEDACTA : Announces First Surgery with MectaLock PEEK in Australia
EQ
2019MEDACTA : publishes CSR Report and pays a Special 20 Year Anniversary Fidelity B..
EQ
2019MEDACTA : Receives CE Marking for the Lateralized Glenosphere
EQ
2019MEDACTA GROUP SA : 2019 Half-Year results
EQ
More news
Financials (EUR)
Sales 2019 309 M
EBIT 2019 59,1 M
Net income 2019 35,3 M
Debt 2019 142 M
Yield 2019 0,58%
P/E ratio 2019 43,7x
P/E ratio 2020 28,4x
EV / Sales2019 5,55x
EV / Sales2020 4,86x
Capitalization 1 571 M
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 74,28  €
Last Close Price 78,55  €
Spread / Highest target 6,68%
Spread / Average Target -5,44%
Spread / Lowest Target -15,1%
EPS Revisions
Managers
NameTitle
Francesco Siccardi Chief Executive Officer
Alberto Siccardi Chairman
Corrado Farsetta Chief Financial Officer
Maria Luisa Siccardi Tonolli Director
Sector and Competitors
1st jan.Capitalization (M$)
MEDACTA GROUP SA14.92%1 705
MEDTRONIC PLC0.36%151 884
BAXTER INTERNATIONAL INC.10.82%47 313
HOYA CORPORATION-0.10%34 270
ZIMMER BIOMET HOLDINGS5.15%32 373
DEXCOM, INC.33.15%26 677